COVID-19

Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers

Comprehensive Platform Combines Masimo’s Industry-leading Biosensing Capabilities with Snapdragon Wearable Platforms to Expand the Wear OS by Google™ Ecosystem IRVINE,…

3 months ago

Masimo Partners with Google to Develop a Reference Platform That Helps Device Manufacturers Bring High-performing Wear OS Smartwatches to Market

Comprehensive Smartwatch Reference Platform to Include Key Hardware and Software Components, Including Industry-leading Masimo Biosensing Capabilities IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:…

3 months ago

US Digital Health Market Insights & Forecast 2024-2028, with Profiles of Leading Players Apple, McKesson, Alphabet, Cisco Systems, Cerner and Allscripts Healthcare Solutions – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "US Digital Health Market (by Technology & Component): Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's…

3 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune…

3 months ago

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB…

3 months ago

Canada Health Infoway, Canadian Medical Association Survey Shows Physicians are Embracing Connected Care Solutions

TORONTO, Sept. 12, 2024 /CNW/ - A new survey shows that while Canadian physicians are embracing digital tools to support quality…

4 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…

4 months ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Centers for Disease Control and Prevention (CDC) reports death rate due to COVID-19 has continued to increase throughout 2024 Immunocompromised…

4 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination…

4 months ago

BryceTech Strengthens Biosecurity and Defense Capabilities with New Divisions

ALEXANDRIA, Va., Sept. 11, 2024 /PRNewswire/ -- In response to the increasing demand for technological innovation in national security, BryceTech…

4 months ago